Company news
Changchun Bcht Biotechnology Co. Class A (SSE:688276) news
Changchun Bcht Biotechnology Co. Class A news releases on 6ix. Latest, Sep 23, 2026: "Changchun Bcht Biotechnology Co."Announcement on Voluntary Disclosure…
Press releases & updates
"Changchun Bcht Biotechnology Co."Announcement on Voluntary Disclosure Regarding the Acceptance of the Clinical Trial Application for the Combination Formulation of Recombinant Human Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibody Injection
September 22, 2026
"Changchun Bcht Biotechnology Co."Semi-annual Report for 2026
August 20, 2026
"Changchun Bcht Biotechnology Co."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 12, 2026
"Changchun Bcht Biotechnology Co."Announcement on Return of Previously Used Funds Raised for Temporary Working Capital Supplement and Use of a Portion of Idle Funds Raised for Temporary Working Capital Supplement
June 30, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Jilin Jurisdiction
May 11, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 30, 2026
Notice on Convening the 2025 Annual General Meeting
April 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 13, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Expected Loss in Performance for 2025
January 16, 2026
Announcement on Change of Sponsor Representative for Continuous Supervision
December 25, 2025
Announcement on Election of Employee Representative Directors for the 6th Board of Directors
November 14, 2025
Announcement on Voluntary Disclosure of Approval of Clinical Trial Application for Adsorbed Acellular DTPa (Dual-component) Combined Vaccine (for Adults and Adolescents)
November 12, 2025
Announcement on Making Provisions for Asset Impairment for the First Three Quarters of 2025
October 30, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 23, 2025
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Trivalent Influenza Virus Subunits Vaccine (BK-01 Adjuvant)
October 13, 2025
Announcement on Voluntary Disclosure of Approval for Diphtheria, Tetanus, Pertussis (Acellular, Component) and Haemophilus Type b Conjugate Vaccine, Adsorbed
October 9, 2025
Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Semi-annual Report
September 29, 2025
Announcement on Release of Freezing of Some Shareholders' Shares
September 24, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 16, 2025
2025 Semi-annual Report
August 29, 2025
Announcement on Voluntary Disclosure of Approval of Marketing Authorization Application for Live Attenuated Nasal-Spray Influenza Vaccine
August 25, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 22, 2025
Announcement on the Return of Raised Funds Formerly Used to Temporarily Supplement Current Capital and Use of Partial Idle Raised Funds to Temporarily Supplement Current Capital
July 25, 2025
Announcement on Voluntary Disclosure of Obtaining Approval of Clinical Trial for Split-Virion Influenza Vaccine (BK-01 Adjuvant)
June 19, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 10, 2025
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Recombinant Zoster Vaccine (CHO Cell)
June 4, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Jilin Jurisdiction
May 19, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 13, 2025
Announcement on 2024 Annual Profit Distribution Scheme
April 20, 2025
Announcement on Convening Performance Briefing for 2024 and Q1 2025
April 11, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
April 7, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
March 20, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 25, 2025
Announcement on Resignation of Director and Senior Management Member
February 14, 2025
Announcement on Progress of Signing Investment Agreement and Conducting Outward Investment
January 23, 2025
Announcement on Expiration of the Plan of Shareholding Reduction through Call Auction by Shareholders and the Results
January 15, 2025
Announcement on the Approval of Voluntary Disclosure of Clinical Trial Application for Freeze-dried Haemophilus Influenzae Type b Conjugate Vaccine
December 25, 2024
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA Vaccine
December 20, 2024
Announcement on Completing Term Change and Election of the Board of Directors and the Board of Supervisors and Appointing Senior Management Members and Securities Affairs Representative
December 10, 2024
Announcement on Electing Employee Representative Supervisor of the 6th Board of Supervisors
November 22, 2024
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares to 5%
November 6, 2024
Report for Q3 2024
October 25, 2024
Announcement on Convening Performance Briefing for Q3 2024
October 18, 2024
Announcement on the Judicial Freezing of Partial Shares Held by Shareholders with over 5% Shareholding
October 8, 2024
Announcement on Shareholding Reduction Plan through Call Auction by Shareholders Holding Over 5% of Shares
September 13, 2024
Announcement on Returning Raised Funds Previously Used to Temporarily Supplement Current Capital and Using Some Idle Raised Funds to Temporarily Supplement Current Capital
August 15, 2024
Announcement on Convening Semi-annual Performance Briefing 2024
August 8, 2024
Announcement on Adjusting the Grant Price of Restricted Stock in the 2022 Restricted Stock Incentive Plan
July 19, 2024